Narrowing the knowledge gaps for melanoma

References

• Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998–1012.
   PubMed Web of Science ®Google Scholar
• Monahan KB, Rozenberg GI, Krishnamurthy J, Johnson SM, Liu W, Bradford MK, Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene. 2010;29:5809–17.
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.
   PubMed Web of Science ®Google Scholar
• Meyle KD, Guldberg P. Genetic risk factors for melanoma. Hum Genet. 2009;126:499–510.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Fisher DE. New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances. Clin Cancer Res. 2011;17:4922–8.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–19.
   PubMed Web of Science ®Google Scholar
• Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail. Biochem Pharmacol. 2010;80:624–37.
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Herlyn M. Resistance to BRAF Inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011;71:7137–40.
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973–7.
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Rosen N. Mutant BRAF melanomas—dependence and resistance. Cancer Cell. 2011;19:11–15.
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18:683–95.
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340–6.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;26:2046–51.
   PubMed Web of Science ®Google Scholar
• Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res. 2008;21:492–3.
   PubMed Web of Science ®Google Scholar
• Box NF, Terzian T. The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res. 2008;21:525–33.
   PubMed Web of Science ®Google Scholar
• Easty DJ, Gray SG, O'Byrne KJ, O'Donnell D, Bennett DC. Receptor tyrosine kinases and their activation in melanoma. Pigment Cell Melanoma Res. 2011;24:446–61.
   PubMedGoogle Scholar
• O'Connell MP, Weeraratna AT. Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell Melanoma Res. 2009;22:724–39.
   PubMedGoogle Scholar
• Strizzi L, Hardy KM, Kirsammer GT, Gerami P, Hendrix MJ. Embryonic signaling in melanoma: potential for diagnosis and therapy. Lab Invest. 2011;91:819–24.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
   PubMed Web of Science ®Google Scholar
• Ernfors P. Cellular origin and developmental mechanisms during the formation of skin melanocytes. Exp Cell Res. 2010;316:1397–407.
   PubMed Web of Science ®Google Scholar
• Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc. 2005;10:153–63.
   PubMedGoogle Scholar
• Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009;15:294–303.
   Google Scholar
• Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol. 2005;15:249–54.
   PubMed Web of Science ®Google Scholar
• Bansal R, Nikiforov MA. Pathways of oncogene-induced senescence in human melanocytic cells. Cell Cycle. 2010;9:2782–8.
   Google Scholar
• Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death—apoptosis, autophagy and senescence. FEBS J. 2010;277:2–21.
   PubMed Web of Science ®Google Scholar
• Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR, Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol. 2006;8:1053–63.
   PubMed Web of Science ®Google Scholar
• Zhuang D, Mannava S, Grachtchouk V, Tang WH, Patil S, Wawrzyniak JA, C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene. 2008;27:6623–34.
   PubMed Web of Science ®Google Scholar
• Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19–20.
   PubMed Web of Science ®Google Scholar
• Haferkamp S, Tran SL, Becker TM, Scurr LL, Kefford RF, Rizos H. The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence. Aging (Albany NY). 2009;1:542–56.
   PubMedGoogle Scholar
• Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 2006;66:9483–91.
   PubMed Web of Science ®Google Scholar
• Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene. 2004;23:4060–7.
   PubMedGoogle Scholar
• Mannava S, Omilian AR, Wawrzyniak JA, Fink EE, Zhuang D, Miecznikowski JC, PP2A-B56alpha controls oncogene-induced senescence in normal and tumor human melanocytic cells. Oncogene. 2011;Aug8 [Epub ahead of print].
   PubMedGoogle Scholar
• Homig-Holzel C, van Doorn R, Vogel C, Germann M, Cecchini MG, Verdegaal E, Antagonistic TSC22D1 variants control BRAF(E600)-induced senescence. EMBO J. 2011;30:1753–65.
   Google Scholar
• Licciulli S, Luise C, Scafetta G, Capra M, Giardina G, Nuciforo P, Pirin inhibits cellular senescence in melanocytic cells. Am J Pathol. 2011;178:2397–406.
   PubMed Web of Science ®Google Scholar
• Miyazaki I, Simizu S, Okumura H, Takagi S, Osada H. A small-molecule inhibitor shows that pirin regulates migration of melanoma cells. Nat Chem Biol. 2010;6:667–73.
   PubMed Web of Science ®Google Scholar
• Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, Sharpless NE, ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci USA. 2007;104:10968–73.
   PubMed Web of Science ®Google Scholar
• Delmas V, Beermann F, Martinozzi S, Carreira S, Ackermann J, Kumasaka M, Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 2007;21:2923–35.
   PubMed Web of Science ®Google Scholar
• Ackermann J, Beermann F. The fibroblast growth factor-2 is not essential for melanoma formation in a transgenic mouse model. Pigment Cell Res. 2005;18:315–19.
   PubMedGoogle Scholar
• Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 1997;11:2822–34.
   PubMed Web of Science ®Google Scholar
• Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, Gray JW, The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet. 2005;37:1047–54.
   PubMed Web of Science ®Google Scholar
• Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;436:117–22.
   PubMed Web of Science ®Google Scholar
• Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol. 2009;174:2367–77.
   PubMedGoogle Scholar
• Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41:544–52.
   PubMed Web of Science ®Google Scholar
• Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet. 2005;37:745–9.
   PubMed Web of Science ®Google Scholar
• Lo RS, Witte ON. Transforming growth factor-beta activation promotes genetic context-dependent invasion of immortalized melanocytes. Cancer Res. 2008;68:4248–57.
   PubMedGoogle Scholar
• Schouwey K, Beermann F. The Notch pathway: hair graying and pigment cell homeostasis. Histol Histopathol. 2008;23:609–19.
   PubMedGoogle Scholar
• Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res. 2009;69:5312–20.
   PubMed Web of Science ®Google Scholar
• Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet. 2011;20:5012–23.
   PubMed Web of Science ®Google Scholar
• Barrett JH, Iles MM, Harland M, Taylor JC, Aitken JF, Andresen PA, Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet. 2011;43:1108–13.
   PubMed Web of Science ®Google Scholar
• Nan H, Qureshi AA, Prescott J, De Vivo I, Han J. Genetic variants in telomere-maintaining genes and skin cancer risk. Hum Genet. 2011;129:247–53.
   PubMed Web of Science ®Google Scholar
• Bataille V, Kato BS, Falchi M, Gardner J, Kimura M, Lens M, Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence in vivo. Cancer Epidemiol Biomarkers Prev. 2007;16:1499–502.
   PubMed Web of Science ®Google Scholar
• Han J, Qureshi AA, Prescott J, Guo Q, Ye L, Hunter DJ, A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol. 2009;129:415–21.
   PubMed Web of Science ®Google Scholar
• Soo JK, Mackenzie Ross AD, Kallenberg DM, Milagre C, Heung Chong W, Chow J, Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression. Pigment Cell Melanoma Res. 2011;24:490–503.
   PubMedGoogle Scholar
• Macgregor S, Montgomery GW, Liu JZ, Zhao ZZ, Henders AK, Stark M, Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet. 2011;43:1114–18.
   PubMed Web of Science ®Google Scholar
• Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011;471:513–17.
   PubMed Web of Science ®Google Scholar
• Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463:191–6.
   PubMed Web of Science ®Google Scholar
• Yang R, Jiang M, Kumar SM, Xu T, Wang F, Xiang L, Generation of melanocytes from induced pluripotent stem cells. J Invest Dermatol. 2011;131:2458–66.
   PubMedGoogle Scholar
• Nissan X, Larribere L, Saidani M, Hurbain I, Delevoye C, Feteira J, Functional melanocytes derived from human pluripotent stem cells engraft into pluristratified epidermis. Proc Natl Acad Sci USA. 2011;108:14861–6.
   PubMedGoogle Scholar